Prevacid NapraPAC Scripts Suggest PPI/NSAID Combos May Thrive Post-Vioxx
This article was originally published in The Tan Sheet
Executive Summary
TAP's Prevacid NapraPAC is among the early winners in the arthritis market following the withdrawal of Merck's Vioxx, IMS Health data suggest